Development of a novel comprehensive therapy targeting aurora kinase-A for adult T cell leukemia

本研究针对成人T细胞白血病(ATL)这一最难治的T淋巴系肿瘤的过继免疫治疗的新进展，重新论证了以人端粒酶逆转录酶(HTERT)为靶点的过继免疫治疗ATL的临床可行性，并论证了Aurora Kinase-A(AURKA)作为ATL新的治疗靶点的潜在优势。此外，我们开始将针对ATL的治疗策略从基于T细胞受体基因修饰的T细胞扩展到新设计的基于嵌合受体基因修饰的T细胞的治疗策略。

In this study, aiming at a development of novel adoptive immunotherapy against adult T-cell leukemia (ATL) which is one of the most treatment-refractory T-lymphoid malignancy, we newly demonstrated the clinical feasibility of adoptive immunotherapy targeting human telomerase reverse transcriptase (hTERT) for the treatment of ATL, and also demonstrated the potential advantage of Aurora kinase-A (AURKA) as a novel therapeutic target for ATL. In addition, we started to extend our therapeutic strategy against ATL from that based on T-cell receptor gene-modified T-cell to newly designed chimeric receptor gene-modified T cell-based one.